Seoul Economic Daily EnglishCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 14:15:07(首尔 15:15)·⟳ 抓取 14:29:37 +14m30s·⚡ 决策 08-30 14:30:59 +1m22s·58.2 天前
JW Pharmaceutical申请bofanglutide二型糖尿病韩国3期IND，较4月授权计划属于程序性推进
本次IND申请验证了4月授权后的执行进展，但不是获批或临床读出，且关键商业化结果在2029年；相对已披露计划、公司收入和市值，短线新增预期差不足以下单。
📄 原文Seoul Economic Daily English↗ 原文
JW Pharmaceutical Seeks Phase 3 Trial for Diabetes Drug After Obesity Bid
JW Pharmaceutical (001060) has applied for approval of a Phase 3 clinical trial in type 2 diabetes for bofanglutide, a…
不做 JW Pharmaceutical（001060.KS）
不做JW Pharmaceutical（001060.KS）：二型糖尿病3期IND申请是4月已预告的程序性推进，非审批通过或临床读出，2029年前缺少可量化收入增量，周末闭市且无法用实时盘口校准追价。
不做 甘李药业（603087.SH）
不做甘李药业（603087.SH）：韩国授权经济条款和适应症推进计划已在4月披露，本次只小幅提高远期里程碑概率，对A股短线业绩和估值的新增催化不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
JW Pharmaceutical在4月已宣布从Gan & Lee取得bofanglutide韩国独家权利，并披露下半年推动肥胖和二型糖尿病3期；8月28日公司新闻稿确认二型糖尿病3期IND提交，属于管线按计划推进。韩国GLP-1市场远期空间存在，但试验样本174例、预计2029年读出，当前没有审批通过、临床疗效新增数据或商业订单，难以形成可执行短线正期望。
消息传播链
- 公司正式披露bofanglutide二型糖尿病3期IND申请，未能确认具体发布时间到分钟。
- 英文媒体转述公司8月28日披露内容并强调肥胖和糖尿病3期并行推进。市场反应:当时韩国市场周末闭市，无法形成即时成交反应。
关键理由
- bofanglutide若商业化可把GLP-1注射频率从每周一次降至两周一次，对韩国代谢病市场有远期差异化价值。
- 量级句：JW Pharmaceutical近12个月收入约8209亿韩元、市值约6257亿韩元；本事件当前只新增174例3期IND申请和远期2029年读出路径，尚无可确认销售增量或利润贡献。
- Gan & Lee的韩国授权总潜在交易额为8110万美元，但该经济利益已在4月签约时披露，本次仅提高远期里程碑兑现概率。
主要风险
- 本次是IND申请而非MFDS批准，若审评延迟或要求补充资料，管线节奏仍可能后移。
- GLP-1赛道竞争拥挤，bofanglutide到2029年读出时的疗效、安全性、定价和医保支付仍无法判断。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-04-09 · 影响 weakens
4月授权公告已披露今年下半年推进肥胖和二型糖尿病3期，本次IND申请的预期差有限。
检索:JW Pharmaceutical bofanglutide April 2026 Phase 3 obesity diabetes planned second half 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
糖尿病3期预计到2029年2月才完成，当前不产生短期收入或利润增量。
检索:JW Pharmaceutical bofanglutide Phase 3 diabetes trial completion February 2029 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例证据不足叠加事件程序性，促使最终不追多JW Pharmaceutical或甘李药业。
方向:未取得足够同市场、同阶段的GLP-1授权后IND申请先例；仅能判断IND申请通常弱于IND获批、临床读出和商业化授权签约。
涨幅量级:缺少可用于校准短线涨幅的高相似先例，因此不能用先例支持tp/sl或追价。
形态:4月同药物授权公告已触发股价上涨报道，后续预期内IND推进更容易出现边际递减。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 1,945 字
JW Pharmaceutical (001060) has applied for approval of a Phase 3 clinical trial in type 2 diabetes for bofanglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist candidate given once every two weeks. The filing follows an earlier Phase 3 application for the same drug as an obesity treatment, putting late-stage development of both indications on parallel tracks.
JW Pharmaceutical said on the 28th that it had submitted an investigational new drug (IND) application for the type 2 diabetes indication to the Ministry of Food and Drug Safety. The trial will enroll 174 patients in South Korea whose blood sugar remained inadequately controlled despite combined treatment with metformin and a sodium-glucose cotransporter-2 (SGLT-2) inhibitor. Starting in January, the study will compare the efficacy and safety of bofanglutide added to existing therapy against placebo through February 2029.
Bofanglutide is a GLP-1 receptor agonist for which JW Pharmaceutical secured exclusive development and commercialization rights in South Korea from China's Gan & Lee Pharmaceuticals in April. Unlike existing weekly GLP-1 treatments, it is being developed as a subcutaneous injection administered once every two weeks. If commercialized, it would reduce annual injections for obesity and diabetes patients to 26 from 52.
The company previously filed a Phase 3 IND application to evaluate the weight-loss efficacy and safety of bofanglutide in 300 adults with obesity or excess weight. That trial is scheduled to begin in December and conclude in March 2029. If both studies proceed as planned, Phase 3 results for the obesity and diabetes indications are expected in succession in the first half of 2029.
"We will conduct the trials without setbacks in order to strengthen our metabolic disease pipeline spanning obesity and diabetes, and to offer patients a new treatment option with greater dosing convenience," a JW Pharmaceutical official said.
JW Pharmaceutical said on the 28th that it had submitted an investigational new drug (IND) application for the type 2 diabetes indication to the Ministry of Food and Drug Safety. The trial will enroll 174 patients in South Korea whose blood sugar remained inadequately controlled despite combined treatment with metformin and a sodium-glucose cotransporter-2 (SGLT-2) inhibitor. Starting in January, the study will compare the efficacy and safety of bofanglutide added to existing therapy against placebo through February 2029.
Bofanglutide is a GLP-1 receptor agonist for which JW Pharmaceutical secured exclusive development and commercialization rights in South Korea from China's Gan & Lee Pharmaceuticals in April. Unlike existing weekly GLP-1 treatments, it is being developed as a subcutaneous injection administered once every two weeks. If commercialized, it would reduce annual injections for obesity and diabetes patients to 26 from 52.
The company previously filed a Phase 3 IND application to evaluate the weight-loss efficacy and safety of bofanglutide in 300 adults with obesity or excess weight. That trial is scheduled to begin in December and conclude in March 2029. If both studies proceed as planned, Phase 3 results for the obesity and diabetes indications are expected in succession in the first half of 2029.
"We will conduct the trials without setbacks in order to strengthen our metabolic disease pipeline spanning obesity and diabetes, and to offer patients a new treatment option with greater dosing convenience," a JW Pharmaceutical official said.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。